Filtered By:
Drug: Rituxan
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 5036 results found since Jan 2013.
Treatment of new-onset primary central nervous system lymphoma in elderly patients using RMPV chemotherapy: a single-institution experience
Int J Hematol. 2023 Jul 1. doi: 10.1007/s12185-023-03632-9. Online ahead of print.ABSTRACTThe prognosis of primary central nervous system lymphoma (PCNSL) in the elderly remains poor. We aimed to evaluate the outcome of rituximab, methotrexate, procarbazine, and vincristine (RMPV) chemotherapy in elderly patients with new-onset PCNSL. Twenty-eight patients aged ≥ 70 years treated for PCNSL between 2010 and 2020 were examined retrospectively. Nineteen patients received RMPV and nine did not qualify. Patients received five to seven cycles of RMPV plus response-adapted whole-brain radiotherapy (WBRT) and cytarabine. Ten of ...
Source: International Journal of Hematology - July 1, 2023 Category: Hematology Authors: Michiharu Yoshida Takeharu Kato Takeshi Hiu Yoshitaka Imaizumi Simpei Morimoto Daisuke Niino Susumu Yamaguchi Shiro Baba Kenta Ujifuku Koichi Yoshida Ayaka Matsuo Yoichi Morofuji Tsuyoshi Izumo Shinji Okano Yasushi Miyazaki Takayuki Matsuo Source Type: research
Clinical relevance of molecular aspects in extranodal marginal zone lymphoma: a critical appraisal
Ther Adv Med Oncol. 2023 Jun 22;15:17588359231183565. doi: 10.1177/17588359231183565. eCollection 2023.ABSTRACTExtranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) is among the more common types of lymphoma accounting for up to 8% of newly diagnosed lymphoma cases. As opposed to other B-cell lymphomas, however, no predominant genetic hallmark has been defined in MALT lymphoma, but different localizations appear to be affected by different, sometimes distinct changes. Nonetheless, a high proportion of these genetic changes reported in MALT lymphomas dysregulate the pathways leadi...
Source: Adv Data - June 30, 2023 Category: Epidemiology Authors: Markus Raderer Barbara Kiesewetter Ming-Qing Du Source Type: research
Treatment with Biologic Drugs in Pediatric Beh çet’s Disease: A Comprehensive Analysis of the Published Data
ConclusionsThe presented systematic literature search revealed that TNF- α inhibitors followed by interferons were the most frequently used biologic drugs in pediatric BD. Both group of biologic treatments appeared to be effective and have an acceptable safety profile in pediatric BD. However, controlled studies are required for analyzing indications for biologic treatm ents in pediatric BD.
Source: BioDrugs - June 29, 2023 Category: Drugs & Pharmacology Source Type: research
Complement system in Anti-CD20 mAb therapy for cancer: A mini-review
Int J Immunopathol Pharmacol. 2023 Jan-Dec;37:3946320231181464. doi: 10.1177/03946320231181464.ABSTRACTThe complement system is an important part of innate immunity. Through complement-dependent cytotoxicity (CDC), it plays an important role in the clearance of invading pathogens but also cancerous host cells. Therapy with anti-CD20 monoclonal antibodies (mAbs), for example, rituximab and ofatumumab, is a well-established treatment for lymphoid malignancies, and CDC is one of the main mechanisms underlying their anti-cancer activity. However, there are still some issues with the clinical application of anti-CD20 antibodies...
Source: Cancer Control - June 26, 2023 Category: Cancer & Oncology Authors: Yiwen Gao Source Type: research
Treatment pattern of chronic lymphocytic leukemia/small lymphocytic lymphoma in Korea: a multicenter retrospective study (KCSG LY20-06)
CONCLUSIONS: Age and reimbursement mainly influenced treatment strategies. Greater effort to apply risk stratifications into practice and clinical trials for novel agents could help improve treatment outcomes in Korean patients.PMID:37357604 | DOI:10.3904/kjim.2022.408
Source: The Korean Journal of Internal Medicine - June 26, 2023 Category: Internal Medicine Authors: Jung Sun Kim Tae Min Kim Myoung Joo Kang Sung Ae Koh Hyunkyung Park Seung-Hyun Nam Jae Joon Han Gyeong-Won Lee Young Jin Yuh Hee Jeong Lee Jung Hye Choi Source Type: research
The comprehensive expression of BCL2 family genes determines the prognosis of diffuse large B-cell lymphoma
Biochem Biophys Res Commun. 2023 Jun 19;673:36-43. doi: 10.1016/j.bbrc.2023.06.061. Online ahead of print.ABSTRACTDiffuse large B-cell lymphoma (DLBCL) is a prevalent and aggressive non-Hodgkin's lymphoma, and 40% of patients succumb to death. Despite numerous clinical trials aimed at developing treatment strategies beyond the conventional R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen, there have been no positive results thus far. Although the selective BCL2 inhibitor venetoclax has shown remarkable efficacy in chronic lymphocytic leukemia, its therapeutic effect in DLBCL was limite...
Source: Cell Research - June 25, 2023 Category: Cytology Authors: Jin Roh Hyo-Kyung Pak Seongfeel Jeong Sewon Hwang Do Eon Kim Hwal-Seok Choi So-Jeong Kim Hyunji Kim Hyungwoo Cho Joon Seong Park Seong Hyun Jeong Yoon Seok Choi Jae Ho Han Dok Hyun Yoon Chan-Sik Park Source Type: research
Association Between New 340B Program Participation and Commercial Insurance Spending on Outpatient Biologic Oncology Drugs
CONCLUSIONS AND RELEVANCE: In this cohort study, new 340B participation was associated with statistically significant higher oncological drug episode spending compared with nonparticipants after changes in 340B inclusion rules in 2010. These findings raise questions about unintended consequences of the 340B program on drug spending from the commercially insured population.PMID:37351874 | DOI:10.1001/jamahealthforum.2023.1485
Source: Cancer Control - June 23, 2023 Category: Cancer & Oncology Authors: Jessica Chang Pinar Karaca-Mandic Sayeh Nikpay Molly Moore Jeffery Source Type: research
Delayed spontaneous remission of acquired factor V inhibitor refractory to immunosuppressive therapy with pregnancy-associated improvement
Discussion: The use of an activated bypassing agent for bleeding control is effective in patients with severe AFVI. The presented case is unique because the treatment regimens included multiple combinations of immunosuppressive agents. This demonstrates that AFVI patients may undergo spontaneous remission even after multiple courses of ineffective immunosuppressive protocols. Additionally, pregnancy-associated improvement of AFVI is an important finding that warrants further investigation.PMID:37334173 | PMC:PMC10272408 | DOI:10.3389/pore.2023.1611250
Source: Pathology Oncology Research - June 19, 2023 Category: Pathology Authors: Andrea Cegl édi J ános Dolgos M ónika Fekete L ászló Gopcsa Andrea V árkonyi Be áta Vilimi G ábor Mikala Imre Bod ó Source Type: research
Rituximab plus multiagent chemotherapy for newly diagnosed CD20-positive acute lymphoblastic leukemia: a prospective phase II study
CONCLUSIONS: The addition of rituximab to conventional chemotherapy for CD20-positive ALL is effective and tolerable (Clinicaltrials. gov NCT01429610).PMID:37334511 | DOI:10.3904/kjim.2022.401
Source: The Korean Journal of Internal Medicine - June 19, 2023 Category: Internal Medicine Authors: Dong Won Baek Han-Seung Park Sang Kyun Sohn Dae Young Kim Inho Kim Jae-Sook Ahn Young Rok Do Se Ryeon Lee Hyeon-Seok Eom Won-Sik Lee Sung-Hyun Kim Ho Sup Lee Yoo Jin Lee Joon Ho Moon Je-Hwan Lee Adult Acute Lymphoblastic Leukemia Working Party, the Korean Source Type: research
